Recently, the innovative drug sector has experienced a surge! Catalyzed by a major overseas billion-dollar cooperation deal, Hengrui Pharmaceuticals saw its stock price soar by over 24% on July 28, driving the entire innovative drug sector higher. According to the National Medical Products Administration, in the first half of this year, China approved 43 innovative drugs and 45 innovative medical devices, representing year-on-year growth of 59% and 87%, respectively. The benefits of reform policies are being converted into momentum for industrial development. Additionally, Citi has raised target prices for several Chinese pharmaceutical companies, expressing a bullish outlook on next-generation immuno-oncology therapies. With continuous policy support, business development (BD) collaborations are expected to accelerate the revaluation of innovative drug companies. Will you be positioning yourself in the innovative drug sector?